The Lead Episode 166: A Discussion of Relationship Between Time-to-First Atrial Tachyarrhythmia Recurrence and Atrial Fibrillation Burden: Implications for Trial Design
Availability
On-Demand
Cost
$0.00
Credit Offered
No Credit Offered

In this episode of The Lead recorded at EHRA, host Christopher Kowalewski, MD, is joined by Tina Baykaner, MD, MPH, and Sanjiv M. Narayan, MD, PhD, FHRS, to discuss the journal article, Relationship Between Time-to-First Atrial Tachyarrhythmia Recurrence and Atrial Fibrillation Burden: Implications for Trial Design. Together, they examine the relationship between time to first atrial tachyarrhythmia recurrence and atrial fibrillation burden and discuss the implications of these measures for clinical trial design.

  • Review the relationship between time-to-first atrial tachyarrhythmia recurrence and atrial fibrillation burden.
  • Discuss how different measures of atrial fibrillation recurrence and burden may influence the interpretation of clinical trial outcomes.
  • Examine the implications of atrial fibrillation burden and time-to-first recurrence for the design of future atrial fibrillation trials.

Podcast Contributors

Host: Christopher Kowalewski, MD

 

Guests: Tina Baykaner, MD, MPH and Sanjiv M. Narayan, MD, PhD, FHRS

All relevant financial relationships have been mitigated.

Host and Contributor Disclosure(s):

C. Kowalewski

  • No relevant disclosures

 

T. Baykaner

  • Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific
  • Research: NIH, Boston Scientific

 

S. Narayan

  • Honoraria/Speaking/Consulting Fee: UpToDate, Inc, LifeSignals, Abbott Medical, TDK Inc.
  • Research: National Institutes for Health
  • Intellectual Property Rights: University of California Regents
  • Stocks – Privately Held: Physcade


Staff Disclosu
re(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):

S. Sailor: No relevant financial relationships with ineligible companies to disclose.
E. Downward: No relevant financial relationships with ineligible companies to disclose.